
Lipocine (LPCN) Stock Forecast & Price Target
Lipocine (LPCN) Analyst Ratings
Bulls say
Lipocine is a clinical-stage biopharmaceutical company that is focused on the development and commercialization of oral delivery solutions for existing drugs, with its lead product candidate TLANDO showing promising results in its Phase 3 PPD trial. The company's strong financials, including a net loss of $3.2M and total revenue of $0.1M in the 3Q25, suggest its ability to continue its research and development efforts. With its continued progress and potential in the emerging treatment market for postpartum depression, Lipocine's stock has a positive outlook for growth in the future.
Bears say
Lipocine is a clinical-stage biopharmaceutical company that is heavily reliant on its proprietary drug delivery technology to drive its future growth. However, the company has a limited pipeline and a significant portion of its revenue comes from developing products for corporate partners, making it vulnerable to collaboration setbacks. Additionally, Lipocine has a history of incurring losses and its current cash reserves are significantly lower than its long-term debt, suggesting potential financial difficulties in the future.
This aggregate rating is based on analysts' research of Lipocine and is not a guaranteed prediction by Public.com or investment advice.
Lipocine (LPCN) Analyst Forecast & Price Prediction
Start investing in Lipocine (LPCN)
Order type
Buy in
Order amount
Est. shares
0 shares